Browsing by Subject "adalimumab"

Now showing items 1-3 of 3

Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: Dosing patterns and related costs in Switzerland from a payers perspective

Zeidler, Jan; Mittendorf, Thomas; Müller, Rüdiger; Kempis, Johannes von (Heidelberg : Springer Verlag, 2012)

Background: To obtain detailed real-life data on costs and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in patients treated in Switzerland. Methods: Administrative claims ...
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany

Neubauer, Sarah; Cifaldi, Mary; Mittendorf, Thomas; Ganguli, Arijit; Wolff, Malte; Zeidler, Jan (Berlin : Springer Verlag, 2014)

Objective: To obtain detailed real-world data on persistence and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in rheumatoid arthritis (RA) patients treated in Germany. ...
Regional differences in health care of patients with inflammatory bowel disease in Germany

Lange, Ansgar; Prenzler, Anne; Bachmann, Oliver; Linder, Roland; Neubauer, Sarah; Zeidler, Jan; Manns, Michael P.; Schulenburg, Johann-Matthias Graf von der (Heidelberg : Springer Verlag, 2015)

Background: The regional availability of specialized physicians is an important aspect in healthcare of patients with IBD. The association between physician density and healthcare is not yet clear. Most studies did not ...

Now showing items 1-3 of 3

Browse